Patrick Gallagher has 20 years of healthcare experience on Wall Street including alternative investments, research and marketing in both the public and private markets. He co-founded Black Diamond Research, LLC (“BDR”), an independent sell-side research firm specializing in healthcare investing, financing and operations, serving the institutional investing community at large. Patrick was Chief Executive Officer of BDR until 2010 and oversaw institutional research and sales. Prior to 2001, he held various sales positions at Kidder Peabody, PaineWebber and New Vernon Associates.
Patrick served as VP of Business Development and Investor Relations as well as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology. He also has served as an advisor to CHD Biosciences, a novel antimicrobial company. Mr. Gallagher serves on the board of directors of BioSig Technologies, Inc, a medical device company that is developing a proprietary technology platform in the electrophysiology space as well as Protea Biosciences, a molecular information/diagnostic company with the unique ability to provide direct analysis of cells.
Mr. Gallagher received his BS from the University of Vermont, his MBA from Pennsylvania State University and is a CFA charter holder.